Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 0.0 | 0.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 0.61 | 2.01 |
NAV | ₹19.24 | ₹62.60 |
Fund Started | 11 Jan 2021 | 18 Jun 2012 |
Fund Size | ₹3522.13 Cr | ₹3332.80 Cr |
Exit Load | - | Exit load of 1% if redeemed within 1 month. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 29.68% | 10.52% |
3 Year | 20.85% | 11.27% |
5 Year | - | 13.52% |
1 Year
3 Year
5 Year
Equity | 0.00% | 98.56% |
Cash | 100.00% | 1.44% |
Equity
Cash
Top 10 Holdings | - |
|
Top 10 Holdings
Name | Assets |
---|---|
Gilead Sciences Inc. (USA) | 2.87% |
Corteva Inc. | 2.80% |
The Walt Disney Company | 2.73% |
Bristol-Myers Squibb Co | 2.68% |
Bio-Rad Laboratories Inc A | 2.66% |
Altria Group Inc | 2.63% |
Estee Lauder Stock | 2.50% |
Veeva Systems Inc. | 2.49% |
Agilent Technologies Inc | 2.46% |
The Boeing Co | 2.46% |
Name | Arjun Khanna | Ritesh Lunawat |
Start Date | 12 Jul 2023 | 12 Jun 2023 |
Name
Start Date
Description | The scheme seeks to provide long-term capital appreciation by investing in units of overseas ETF's and/ or Index Fund based on NASDAQ 100 Index. | The investment objective of ICICI Prudential US Bluechip Equity Fund is to provide long term capital appreciation to investors by primarily investing in equity and equity related securities of companies listed on recognized stock exchanges in the United States of America. The Scheme shall also invest in ADRs/GDRs issued by Indian and foreign companies. |
Launch Date | 11 Jan 2021 | 18 Jun 2012 |
Description
Launch Date